MOTS-c Dosing Protocol: Frequency, Timing & Cycles
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a mitochondria-derived peptide that has attracted substantial interest in metabolic and longevity research. Unlike conventional peptide hormones, MOTS-c is encoded within mitochondrial DNA, which gives it a distinct signaling profile. This page summarizes the dosing schedules, timing windows, and cycle structures reported in preclinical and early human research. All information is for research reference only.
Background: Why Protocol Structure Matters for MOTS-c
MOTS-c exerts much of its activity through the AMPK pathway, promoting glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. Research in mice has shown that its effects on insulin sensitivity and physical endurance are dose-dependent and frequency-sensitive. Irregular administration appears to produce weaker outcomes than consistent scheduled dosing, which is why the framing as a "protocol" rather than just a dose is meaningful.
If you are looking specifically for the per-injection amounts used in research, the companion MOTS-c dosage guide covers those figures in detail. This article focuses on the scheduling layer: how often, when, and for how long.
Research-Reported Dosing Schedules
The table below summarizes schedules that appear across the published and preprint literature. These are research-reported figures, not dosing advice. They describe what investigators used in controlled settings.
| Protocol Type | Frequency | Reported Dose Range | Duration | Primary Focus |
|---|---|---|---|---|
| Daily maintenance | 7 days/week | 5 mg per injection | 4 weeks | Metabolic markers, insulin sensitivity |
| Alternate-day | 3 to 4 days/week | 5 to 10 mg per injection | 6 to 8 weeks | Body composition, endurance capacity |
| High-frequency burst | 5 days on / 2 days off | 10 mg per injection | 4 weeks | Exercise performance, mitochondrial density |
| Weekly loading | 1 to 2 days/week | 10 mg per injection | 8 to 12 weeks | Aging biomarkers, NAD metabolism |
The most commonly referenced protocol across metabolic studies is the alternate-day schedule at 5 mg, run for six to eight weeks. Daily dosing appears in studies with shorter windows where investigators needed faster signal generation. Weekly loading protocols tend to appear in longevity-focused work where the timeline spans months rather than weeks.
Timing Within the Day
Animal studies have consistently administered MOTS-c in the morning, often before the active phase begins. Several rodent papers correlate morning dosing with superior AMPK activation compared to evening controls. The reasoning is that MOTS-c amplifies the metabolic response to activity, so administering it before the period of greatest movement may produce a stronger effect on downstream markers.
In studies that examined exercise-coupled protocols, the compound was given 30 to 60 minutes before the exercise bout. This aligns with the observation that MOTS-c circulates transiently and its peak signaling window is relatively short. Subcutaneous delivery is the standard route across virtually all MOTS-c research; it offers consistent bioavailability and is straightforward to replicate. The protocols reference section covers reconstitution and injection technique in detail.
Cycle Length and Off Periods
Most published research runs MOTS-c for 4 to 12 weeks. Unlike some GHRH peptides such as CJC-1295 where receptor desensitization is a documented concern, MOTS-c does not appear to produce receptor downregulation in the same direct way. However, the research community generally structures MOTS-c work with intermittent cycles rather than continuous indefinite dosing, partly because long-term human data simply does not exist.
A widely cited cycle structure in preclinical literature is eight weeks on followed by four weeks off. This structure was used in a notable 2019 study examining MOTS-c and age-related metabolic decline, and it has become a common reference point for how investigators design follow-up work. A shorter four-week cycle with a two-week break also appears in studies focused on acute metabolic improvement rather than sustained effects.
Stacking Considerations in Research
Several studies have examined MOTS-c alongside other metabolic interventions. Pairing with compounds that affect the AMPK or NAD pathway is the most theoretically grounded approach, since MOTS-c itself converges on these targets. Research models that combined caloric restriction with MOTS-c administration saw amplified effects on mitochondrial markers compared to either intervention alone.
In the peptide research context, MOTS-c is sometimes examined alongside SS-31, another mitochondria-targeted compound. Because both act on mitochondrial function via distinct mechanisms, the two are not redundant. If you are reading about SS-31 parameters, the SS-31 peptide dosage guide has the published figures for that compound.
Combinations with growth hormone secretagogues such as ipamorelin are sometimes discussed in longevity research stacks. The rationale involves complementary anabolic and mitochondrial support. That said, simultaneous multi-peptide protocols carry compounded uncertainty because the interaction effects are largely uncharacterized.
What the Research Does Not Clarify
Human dosing data for MOTS-c remains sparse. The majority of the literature is rodent-based, and translating milligram-per-kilogram doses from mice to human-equivalent figures involves assumptions that have not been validated clinically. The optimal frequency for humans, the minimum effective dose, and the precise cycle length that balances effect duration against safety are all open questions. This is why MOTS-c remains a research-only compound.
For a fuller picture of what MOTS-c has produced in controlled settings, including body composition and performance endpoints, see the MOTS-c before and after research summary. For the known adverse signal, the MOTS-c side effects guide covers what the literature has reported.